HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 269 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,163,262 | +29.2% | 292,232 | +23.6% | 0.03% | +26.9% |
| Q2 2023 | $8,639,250 | +3.0% | 236,368 | +7.6% | 0.03% | -3.7% |
| Q1 2023 | $8,386,409 | +51.9% | 219,597 | +61.8% | 0.03% | +107.7% |
| Q3 2021 | $5,521,000 | -10.0% | 135,726 | +0.4% | 0.01% | -18.8% |
| Q2 2021 | $6,137,000 | +13.3% | 135,148 | +4.0% | 0.02% | +6.7% |
| Q1 2021 | $5,416,000 | -4.3% | 129,923 | -1.9% | 0.02% | 0.0% |
| Q4 2020 | $5,657,000 | +63.0% | 132,450 | +0.3% | 0.02% | +25.0% |
| Q3 2020 | $3,470,000 | -36.5% | 132,049 | -35.2% | 0.01% | -42.9% |
| Q2 2020 | $5,465,000 | +56.9% | 203,820 | +5.3% | 0.02% | +10.5% |
| Q1 2020 | $3,483,000 | +42.9% | 193,619 | +40.9% | 0.02% | +46.2% |
| Q4 2019 | $2,437,000 | +398.4% | 137,428 | +336.1% | 0.01% | +333.3% |
| Q3 2019 | $489,000 | -9.6% | 31,512 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $541,000 | +5.0% | 31,512 | -1.5% | 0.00% | -25.0% |
| Q1 2019 | $515,000 | – | 31,997 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |